ArticleCancers2020
Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- Agents for Fluorescence-Guided Glioblastoma Surgery.Pharmaceutics · 2025Review
- Review
- Intraoperative Imaging and Optical Visualization Techniques for Brain Tumor Resection: A Narrative Review.Cancers · 2023Review
- Novel intraoperative strategies for enhancing tumor control: Future directions.Neuro-oncology · 2022Review
- FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma.Brain sciences · 2022Article
- Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.Pharmaceutics · 2022Review
- Glioblastoma vaccine tumor therapy research progress.Chinese neurosurgical journal · 2022Review
- Fluorescent intraoperative navigation: trends and beyond.American journal of nuclear medicine and molecular imaging · 2022Article
- Targeting intracranial patient-derived glioblastoma (GBM) with a NIR-I fluorescent immunoconjugate for facilitating its image-guided resection.RSC advances · 2020Article
- Near-Infrared Activated Cyanine Dyes As Agents for Photothermal Therapy and Diagnosis of Tumors.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is one of the most aggressive tumors and its 5-year survival is approximately 5%. Fluorescence-guided surgery (FGS) improves the extent of resection and leads to better prognosis. Molecular near-infrared (NIR) imaging appears to outperform conventional FGS, however, novel molecular targets need to be identified in GBM. Proteoglycan glypican-1 (GPC-1) is believed to be such a target as it is highly expressed in GBM and is associated with poor prognosis. We hypothesize that an anti-GPC-1 antibody, Miltuximab
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.